#Germany #Munich #Seegene #STAgora #PCR Workflows

Seegene Sets New Standard in Molecular Diagnostics at ESCMID Global 2026

Seegene Inc., a renowned leader in molecular diagnostics, recently showcased its latest innovations at ESCMID Global 2026, held in Munich, Germany from April 17 to 21. The event highlighted the company's STAgora™ platform, which focuses on real-time data analytics integrated with automated PCR workflows, a significant advancement for laboratories worldwide.

Transformative Data Analytics

The STAgora™ platform enables laboratories to aggregate PCR test data in real time, offering a clearer understanding of infection trends. As Young Seag Baeg, Seegene's New Business Officer, noted, "STAgora™ was created to consolidate infection data generated globally. By employing aggregated statistics, it allows for a more vivid picture of the ongoing epidemiological situation." This robust platform empowers medical professionals to make informed decisions based on the latest data, ultimately enhancing public health responses.

At the Seegene exhibition booth, visitors had the opportunity to experience live simulations of STAgora™. These included interactive touch-screen demonstrations that displayed the platform's intuitive user interface and its capabilities in visualizing aggregated test data. The engaging experience showcased how seamless integration of real-time analytics could significantly improve laboratory efficiency and responsiveness to emerging health threats.

Enhanced PCR Workflows with CURECA™

In addition to STAgora™, Seegene also introduced its upgraded CURECA™ system during the conference. This automated PCR workflow model simplifies processes such as sample preparation, nucleic acid extraction, and result processing. Attendees were particularly impressed with CURECA™'s modular architecture, which can be adapted to fit diverse laboratory setups while ensuring optimized overall performance.

Key discussions took place regarding the potential applications of both STAgora™ and CURECA™ in active clinical settings and research environments. Experts recognized the importance of translating advanced technologies into practical solutions that can tackle real-world challenges. The platform's ability to support simultaneous detection of multiple pathogens allows for broader analysis of infection patterns.

The Gathering of Experts

During the conference, Seegene reported a significant interest from clinical labs, research institutions, and industry experts in exploring automated PCR workflows. Daniel Shin, Seegene’s Executive Vice President and Chief Global Sales and Marketing Officer, highlighted the keen response to real-time data analytics, noting, "The interest was palpable throughout the congress. We aim to expand pilot programs with laboratories and healthcare facilities to comprehensively assess STAgora™ and support potential future applications."

Furthermore, specialists in the field praised STAgora™ for its user-friendly approach to data analysis and visualization tools. The platform allows for simultaneous displays of regional infection trends alongside aggregated test results, which experts deemed critical for effective decision-making in mitigating disease outbreaks.

Bridging to the Future

Seegene's comprehensive approach, incorporating syndromic PCR testing and its innovative diagnostic technologies, emphasizes the company's commitment to enhancing public health efforts. By advancing platforms like STAgora™ and CURECA™, Seegene aims to lead the charge in making molecular diagnostics more efficient and accessible.

Over the years, Seegene has established itself as a key player in the field of molecular diagnostics, particularly noted for its multiplex PCR technology capable of detecting various pathogens in a single test. This technology has proven essential during global health crises, such as the COVID-19 pandemic, during which Seegene provided millions of tests worldwide.

As Seegene moves forward, its focus remains on expanding access to molecular diagnostics and strengthening global infectious disease prevention efforts, further solidifying its role as an industry innovator in laboratory automation and data analysis.